CSIMarket


Protalix Biotherapeutics inc   (PLX)
Other Ticker:  
 


 

Protalix Biotherapeutics inc

PLX's Financial Statements and Analysis



Protalix Biotherapeutics inc narrowed forth quarter of 2023 net loss per share of $-0.04 compare to net loss per share of $-0.07 recorded in the same quarter a year ago a decrease compare to $-0.04 realized in previous quarter.


forth quarter of 2023
Earnings Per Share Revenues
$ -0.04 $  10 Mill
$+0.03     $+2M     +21.69 %



Protalix Biotherapeutics Inc 's Revenue rose by 21.69 % in forth quarter of 2023 (Dec 31 2023) year on year, to $10 million and advanced by 1.36 % sequentially.


Protalix Biotherapeutics Inc is

More on PLX's Income Statement



Protalix Biotherapeutics Inc 's in theforth quarter of 2023 recorded net loss of $-6.044 million, an increase from net loss of $-3.740 million in IV. Quarter a year ago.

Sequentially net loss advanced

More on PLX's Growth

Protalix Biotherapeutics Inc Inventories
Inventories grew by 13.34 % to $19 million from IV. Quarter a year ago, sequentially inventories fell by -11.76 %. PLX's Cash flow In the forth quarter of 2023 company's net cash flow was $3 million, capital expenditures fell by -0.21317.37%, to $0 millions compare to same quarter a year ago

More on PLX's Cash flow Statement


Protalix Biotherapeutics inc does not pay out common stock dividend.

In trailing twelve-month period Protalix Biotherapeutics inc payed $ -0.01 cash per share, on a free-cash flow basis .

Book value fell by -20.38 % sequentially to $0.36 per share.
Tangible Book value fell to $ 0.36 per share from $ 0.46.

Company issued 8.57 million shares or 10.23 % in Dec 31 2023.
Debt Coverage Ratio was 0.39.

More on PLX's Dividends

 Market Capitalization (Millions) 113
 Shares Outstanding (Millions) 92
 Total Debt (Millions $) 20
 Revenue (TTM) (Millions $) 65
 Net Income (TTM) (Millions $) 8
 Cash Flow (TTM) (Millions $) 7
 Capital Exp. (TTM) (Millions $) -1
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Protalix Biotherapeutics inc does not pay out common stock dividend.

In trailing twelve-month period Protalix Biotherapeutics inc had negative $ -0.01 cash flow per share, on a free-cash flow basis .

Book value fell by -20.38 % sequentially to $0.36 per share.
Tangible Book value fell to $ 0.36 per share from $ 0.46.

Company issued 8.57 million shares or 10.23 % in Dec 31 2023.
Debt Coverage Ratio was 0.39.

More on PLX's Balance Sheets

 Market Capitalization (Millions) 113
 Shares Outstanding (Millions) 92
 Total Debt (Millions $) 20
 Revenue (TTM) (Millions $) 65
 Net Income (TTM) (Millions $) 8
 Cash Flow (TTM) (Millions $) 7
 Capital Exp. (TTM) (Millions $) -1
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Protalix Biotherapeutics inc Earnings

2. Unpacking the Financial Challenges Faced by Protalix Biotherapeutics Inc - An In-Depth Analysis

Protalix Biotherapeutics Inc has shown promising growth in revenue for the financial fourth quarter of 2023, with a significant 21.69% increase compared to the same period a year prior. However, the company also reported a loss of $-0.04 per share, which is a concern for investors. Despite the increase in revenue, the net deficit for the quarter was higher than the previous year, indicating potential financial challenges for the company.
One important factor to consider is the seasonal nature of the business, which may have impacted the decline in inventories for the quarter. While this may have contributed to the increase in revenue, it is essential for the company to closely monitor its inventory level...

Protalix Biotherapeutics Inc's Fiscal Q3 2023 Revenue Takes a Grim -27.061% Hit: Understanding the Factors Behind the Drop

Declining Business Leads to Increase in Shortfall for Protalix Biotherapeutics Inc in Q3 2023
Protalix Biotherapeutics Inc, a leading biopharmaceutical company, experienced declining business in the fiscal third quarter of 2023, resulting in an increase in the company's shortfall. The shortfall per share rose to $-0.04 from $-0.07, indicating a challenging period for the company.
One of the key factors contributing to the increased shortfall was a significant drop in revenue. The company's revenue decreased by -27.061% to $10.35 million from $14.18 million a year ago. This decline can be attributed to various factors such as changes in market dynamics, competition, or even external economic condition...

Protalix Biotherapeutics Inc's Second Quarter Revenue Skyrockets, Stands Out in Biotechnology & Pharmaceuticals Sector!

As a stock market journalist, I have been analyzing the financial results of Protalix Biotherapeutics Inc, and I must say that the numbers are quite impressive. The company's revenue saw a remarkable increase of 300.72% year on year, reaching $35.08 million in the three months ending June 30, 2023. This significant revenue surge is bucking the trend in the Biotechnology and Pharmaceuticals sector, where most of the company's peers experienced business contraction during the same period.
Not only did Protalix Biotherapeutics Inc witness a substantial increase in revenue, but its earnings per share (EPS) also turned positive, reaching $0.21. This is a significant improvement from the previous quarter, wher...

Protalix Biotherapeutics Inc Reports $0.05 Loss per Share in Latest Fiscal Period

Investors in Protalix Biotherapeutics Inc were left disappointed with the company's most recent fiscal period as t...


Date modified: 2024-03-14T16:29:55+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com